Cytoplan Ltd | Reg: 01493205 | Created: 1980-04-24 | Status: active | Type: ltd Cytoplan is a biotechnology company specializing in the discovery and development of novel therapeutics for rare genetic diseases. Founded in 1980, the company focuses on identifying and validating novel targets for disease treatment. Cytoplan’s core technology centers around a proprietary platform that utilizes CRISPR-Cas9 gene editing to create cellular models of human diseases. The company’s primary focus is on developing therapies for rare diseases, particularly those affecting the immune system and neurological pathways. Cytoplan’s research efforts are centered around identifying and characterizing disease-causing genes and developing gene-editing tools to correct these mutations. Cytoplan operates internationally, with a significant presence in Europe and North America. The company employs a team of scientists and engineers dedicated to advancing the understanding and treatment of rare genetic conditions. Cytoplan’s international presence is currently ‘yes’. Cytoplan’s SIC codes encompass a range of industries including Pharmaceuticals, Biotechnology, and Medical Devices. The company is currently a Worker (A rating) and is actively seeking Skilled Worker positions.

Cytoplan Ltd | Reg: 01493205 | Created: 1980-04-24 | Status: active | Type: ltd Cytoplan is a biotechnology company specializing in the discovery and development of novel therapeutics for rare genetic diseases. Founded in 1980, the company focuses on identifying and validating novel targets for disease treatment. Cytoplan’s core technology centers around a proprietary platform that utilizes CRISPR-Cas9 gene editing to create cellular models of human diseases. The company’s primary focus is on developing therapies for rare diseases, particularly those affecting the immune system and neurological pathways. Cytoplan’s research efforts are centered around identifying and characterizing disease-causing genes and developing gene-editing tools to correct these mutations. Cytoplan operates internationally, with a significant presence in Europe and North America. The company employs a team of scientists and engineers dedicated to advancing the understanding and treatment of rare genetic conditions. Cytoplan’s international presence is currently ‘yes’. Cytoplan’s SIC codes encompass a range of industries including Pharmaceuticals, Biotechnology, and Medical Devices. The company is currently a Worker (A rating) and is actively seeking Skilled Worker positions.